Search

Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the world. Although much progress has been made for cardiovascular diseases in diagnosis, treatment and prognosis during the past two decades, the clinical need for a novel diagnostic biomarker and new therapeutic interventions to decrease the cardiovascular disease incidence is ongoing. MicroRNAs (miRNAs) are endogenous, small (∼22 nucleotides), single-stranded, non-coding RNAs that regulate gene expression and are detectable in whole blood, serum, plasma, urine and other body fluids in a highly stable form. Accumulating evidence suggests that miRNAs are potential novel biomarkers with high sensitivity for early diagnosis and modern treatment for cardiovascular diseases. Altered circulating miRNAs expressions have been reported in acute myocardial infarction (AMI), acute coronary syndrome (ACS), stable coronary artery disease, heart failure, atherosclerosis, essential hypertension and stroke. In the present review, we examine more recent data regarding circulating miRNAs and their potential roles in diagnosis, prognosis and therapeutic strategies for cardiovascular diseases. In addition, we briefly present our own recent experience in detecting circulating miRNAs, and the significance of these miRNAs in AMI prognosis.

OBJECTIVE: Circulating microRNAs have been recognized as promising biomarkers for various diseases. The present study aimed to explore the potential roles of circulating miR-149, miR-424 and miR-765 as non-invasive biomarkers for the diagnosis of coronary artery disease in middle-aged (40–60-year-old) patients. METHODS: Sixty-five stable coronary artery disease patients (49–57 years old), 30 unstable coronary artery disease patients (49–58 years old), and 32 non-coronary artery disease patients (49–-57 years old) who were matched for age, sex, smoking habits, hypertension and diabetes were enrolled in this study. Total RNA was isolated from plasma with TRIzol reagent. Circulating miRNA levels were measured by quantitative real-time polymerase chain reaction. RESULTS: Circulating miR-149 levels were decreased 4.49-fold in stable coronary artery disease patients (1.18 ± 0.84) and 5.09-fold in unstable coronary artery disease patients (1.04 ± 0.65) compared with non-coronary artery disease patients (5.30 ± 2.57) (p

The purpose of this study was to explore the diagnostic value of cardiomyocyte-enriched circulating miR-208b, miR-499, miR-378 and miR-424 in acute coronary syndrome patient. This study a single-center, prospective diagnostic study of acute coronary syndrome (ACS) patient. Fifty unstable angina

Background: Coronary artery disease (CAD) is a major public health problem for developed and developing countries and is the single leading cause of death worldwide. Objectives: There is very few evidence regarding changes of both serum Lectin-like oxidized-low density lipoprotein receptor-1 (LOX-1) and adiponectin in patients with CAD accompanied with metabolic syndrome (MS). Here we aimed to evaluate serum levels of LOX-1 and adiponectin in patients with CAD accompanied with MS. Patients and Methods: Thirty patients with coronary artery disease without metabolic syndrome, 30 patients with coronary artery disease and metabolic syndrome, 30 ones with metabolic syndrome and 30 healthy subjects were enrolled. For all subjects, a questionnaire was filled to collect data, and peripheral blood samples were collected aseptically from the antecubital vein to measure serum Lectin-like oxidized-low density lipoprotein receptor-1 and adiponectin levels by enzyme-linked immunosorbent assay. Results: Serum LOX-1 level was highest in CAD + MS group; the difference between control and disease groups was statistically significant (P < 0.001). Adiponectin level had the lowest value in CAD + MS group; the difference between control and disease groups was statistically significant (P < 0.05). No significant differences were observed in serum Lectin-like oxidized-low density lipoprotein receptor-1and adiponectin in patients with different ages and gender. Serum LOX-1 level was changed negatively and linearly (R2 = 0.721) correlated with adiponectin level in different groups. Conclusions: Patient with CAD and MS had higher risk than those with only CAD because of lipid and glucose metabolism abnormalities. Combination measurements of serum LOX-1 and adiponectin levels may be helpful to evaluate the severity of CAD together with MS.

The primary purpose of this paper is to assess the efficacy of the use of the intrauterine device (IUD) as an adjunctive treatment modality, for intrauterine adhesions (IUAs). All eligible literatures were identified by electronic databases including PubMed, Scopus, and Web of Science. Additional relevant articles were identified from citations in these publications. There were 28 studies included for a systematic review. Of these, 5 studies were eligible for meta-analysis and 23 for qualitative assessment only. Twenty-eight studies related to the use of IUDs as ancillary treatment following adhesiolysis were identified. Of these studies, 25 studies at least one of the following methods were carried out as ancillary treatment: Foley catheter, hyaluronic acid gel, hormonal therapy, or amnion graft in addition to the IUD. There was one study that used IUD therapy as a single ancillary treatment. In 2 studies, no adjunctive therapy was used after adhesiolysis. There was a wide range of reported menstrual and fertility outcomes which were associated with the use of IUD combined with other ancillary treatments. At present, the IUD is beneficial in patients with IUA, regardless of stage of adhesions. However, IUD needs to be combined with other ancillary treatments to obtain maximal outcomes, in particular in patients with moderate to severe IUA.

We aimed to explore the diagnostic value of circulating miRNAs (miR-149, miR-208b, miR-378, miR-424, miR-499 and miR-765) in AMI patients, and protective role of miR-208b or miR-378 or metoprolol during H/R injury in H9c2 cell with their underlying mechanisms. 205 AMI patients and 85 healthy